Eli Lilly expanded its research and licensing agreement with Gate Bioscience. The expansion adds over $870 million in potential value to their existing collaboration. This new multi-year deal adds at least one new undisclosed drug target. The partnership focuses on Gate's platform for discovering small-molecule drugs that eliminate disease-causing proteins.
Total compensation includes an upfront payment and research funding. Future payments depend on achieving preclinical, clinical, and commercial milestones. The agreement also includes tiered royalties. Gate Bioscience will lead initial discovery efforts. Eli Lilly will handle later-stage development, manufacturing, and potential commercialization of any new medicines from the collaboration.